Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine/Paclitaxel - Duo Oncology

Next Previous
Drug Profile

Gemcitabine/Paclitaxel - Duo Oncology

Alternative Names: DUO-207

Latest Information Update: 17 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duo Oncology
  • Class Albumins; Amines; Antineoplastics; Deoxyribonucleosides; Diterpenes; Fluorinated hydrocarbons; Ketones; Paclitaxels; Pyrimidine nucleosides; Pyrimidines; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Antimetabolites; DNA synthesis inhibitors; Immunosuppressants; Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Jul 2025 Duo Oncology plans a phase I trial for Cancer in Australia in 2025
  • 13 Feb 2025 Duo Oncology has patent protection for nanomedicine platform technology in the US
  • 23 Jan 2025 Preclinical trials in Cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top